Information Links
Glyxambi
- Section: Diabetes
- Sub Section: Oral and parenteral hypoglycaemics
- Drug Class: Dipeptidyl peptidase 4 inhibitors/SGLT2 inhibitors
- Manufacturer: Boehringer Ingelheim Ltd
To continue enjoying this content, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.